Group
|
DC
|
DC + RES
|
DC + SLN-RES
|
---|
Body weight (g)
|
− 69.4 ± 14.4
|
− 49.9 ± 18.0α+
|
− 12.3 ± 2.8α#π
|
FBS (mg/dl)
|
+ 211.3 ± 92.1
|
+ 98.3 ± 38.6α*
|
+ 38.5 ± 13.6α#δ
|
Insulin (μU/ml)
|
− 4.0 ± 1.2
|
− 1.8 ± 0.9α#π
|
− 0.9 ± 0.2α#π
|
HOMA
|
+ 3.0 ± 1.1
|
+ 2.2 ± 0.8α#
|
+ 0.1 ± 0.04α#πδ
|
- The alteration of parameters was expressed as compared with healthy control group. DC diabetic control, RES resveratrol treatment 10 mg/kg, SLN-RES resveratrol-loaded solid lipid nanoparticles containing 10 mg/kg of resveratrol, FBS fasting blood sugar, HOMA homeostasis model assessment-estimated insulin resistance. Data were expressed as mean ± SD
- αCompared to the DC group
- δThere was a significant difference between RES and SLN-RES group (p < 0.05)
- πRestored to the HC group (there was no significant difference compared to the HC group (p > 0.05)).
- *p < 0.05
- +p < 0.01
- #p < 0.001